Sanofi-Aventis licences Metabolix’ diabetes drugs for $375
Strasbourg/Hayworth – Sanofi-Aventis and Metabolix have entered into a global license and development agreement for the development and commercialisation of small molecules that target GPR119, a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion. Metabolix’ agonists of GPR119 represent a first-in-class oral treatment for type 2 diabetes that function through a new dual mechanism of action. They act directly on the pancreatic beta cell to increase insulin secretion. Furthermore, they stimulate release of the incretin GLP-1 from the intestines. This unique dual action may offer improved glucose homeostasis over existing diabetes therapies, with the potential for weight loss and improved islet health. The agreement includes MBX-2982, an oral GPR119 agonist tested by Metabolex in 3 Phase I trials and currently in a multi-national 28-day Phase 2 clinical study in patients with type 2 diabetes. Under the terms of the agreement, Metabolex will receive an upfront payment and will be eligible to receive milestones up to $375 million. Metabolex is also eligible to receive royalties on worldwide sales of marketed products.